Today: 7 February 2026
Subscribe
Browse Category

TSX:NMG News 14 October 2025

Nouveau Monde Graphite Stock Skyrockets – Future EV Battery King or Overvalued Hype?

Nouveau Monde Graphite Stock Skyrockets – Future EV Battery King or Overvalued Hype?

Stock Performance and Market Reaction NMG’s share price has been exceptionally volatile. After closing US$3.34 on Oct 10, 2025, the stock jumped to around $5.45 by the Oct 13 after-market Benzinga. Trading volume on Oct 13 spiked, with MarketBeat reporting a nearly 300% surge from average daily volumes Marketbeat. This “charge” coincided with broad gains in battery-materials and EV-related equities (e.g. American Battery Tech Co, Almonty Ind. also surged that day Benzinga). Major headline-driven news directly on Oct 13 was limited, suggesting the move was fueled by momentum and speculation. In recent weeks, analyst commentaries have noted this dichotomy: despite
14 October 2025
···

Stock Market Today

MARA stock jumps 22% into weekend as bitcoin whipsaws; Monday risk test looms

MARA stock jumps 22% into weekend as bitcoin whipsaws; Monday risk test looms

7 February 2026
MARA shares jumped 22.4% to $8.24 Friday, trading higher after hours, as the company moved $87 million in bitcoin to major custodians. About 82.4 million MARA shares changed hands. Bitcoin hovered near $68,928 Saturday. A MARA filing showed its general counsel had shares withheld for taxes on vested stock units, not an open market sale.
Apple stock (AAPL) set for Monday test as memory-chip crunch revives iPhone price question

Apple stock (AAPL) set for Monday test as memory-chip crunch revives iPhone price question

7 February 2026
Apple shares closed up 0.8% at $278.12 Friday, then slipped 0.3% after hours. A global DRAM shortage is raising component costs, putting pressure on Apple’s pricing ahead of its Feb. 24 shareholder meeting. CEO Tim Cook said memory prices will rise “sharply” but gave no details on possible iPhone price hikes. Investors await signals before next week’s U.S. inflation data.
Roivant stock surges on brepocitinib skin-disease data; what to watch into Monday

Roivant stock surges on brepocitinib skin-disease data; what to watch into Monday

7 February 2026
Roivant shares surged 22.4% to $25.82 after Phase 2 data showed its drug brepocitinib outperformed placebo in cutaneous sarcoidosis, with no serious adverse events. The company plans a Phase 3 trial in 2026 and has filed for FDA approval in dermatomyositis. Quarterly revenue reached $2 million, with a $313.7 million loss. Cash holdings stood at $4.5 billion.
Go toTop